REGENXBIO Inc. (RGNX)
| Market Cap | 535.59M -5.6% |
| Revenue (ttm) | 153.91M -4.6% |
| Net Income | -175.23M |
| EPS | -3.15 |
| Shares Out | 66.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57,681 |
| Open | 7.80 |
| Previous Close | 7.69 |
| Day's Range | 7.62 - 8.10 |
| 52-Week Range | 5.46 - 16.19 |
| Beta | 1.23 |
| Analysts | Strong Buy |
| Price Target | 24.00 (+196.3%) |
| Earnings Date | Nov 5, 2026 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12... [Read more]
Financial Performance
In 2025, REGENXBIO's revenue was $170.44 million, an increase of 104.54% compared to the previous year's $83.33 million. Losses were -$193.88 million, -14.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price target is $24.0, which is an increase of 196.30% from the latest price.
News
Regenxbio price target lowered to $14 from $15 at BofA
BofA lowered the firm’s price target on Regenxbio (RGNX) to $14 from $15 and keeps a Buy rating on the shares.
Regenxbio price target lowered to $18 from $19 at Mizuho
Mizuho lowered the firm’s price target on Regenxbio (RGNX) to $18 from $19 and keeps an Outperform rating on the shares.
Regenxbio price target lowered to $25 from $29 at Baird
Baird analyst Brian Skorney lowered the firm’s price target on Regenxbio (RGNX) to $25 from $29 and keeps an Outperform rating on the shares. The firm updated its model following…
Regenxbio reports Q3 EPS (62c) vs. ($1.20) last year
Reports Q3 revenue $9.2M, consensus $10.68M. “We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028,” said Curran Simpson,…
REGENXBIO Earnings Call Transcript: Q3 2026
Wet AMD pivotal data are expected this quarter, while a complete RGX-202 BLA is targeted for Q1 2027. Cash totaled $251 million at quarter-end, with runway projected into late Q4 2027.
REGENXBIO Earnings release: Q3 2026
REGENXBIO released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
REGENXBIO Quarterly report: Q3 2026
REGENXBIO has published its Q3 2026 quarterly earnings report on November 5, 2026.
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCEN...
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026 Healthcare Conference.
Regenxbio price target lowered to $19 from $22 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Regenxbio (RGNX) to $19 from $22 and keeps an Outperform rating on the shares.
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m.
REGENXBIO Transcript: Investor update
Pivotal wet AMD results are expected in Q4 2026, with 2027 regulatory submissions planned. Earlier studies showed durable vision and anatomy signals, reduced injection burden and a safety profile panelists viewed as supportive of potential adoption.
REGENXBIO Slides: Investor update
REGENXBIO has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2026.
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- R...
Regenxbio initiated with an Outperform at Mizuho
Mizuho initiated coverage of Regenxbio (RGNX) with an Outperform rating and $22 price target The company is developing gene therapy-based candidates for diseases of high unmet need, the analyst tells…
Regenxbio presents positive 3-year durability data for Surabgene Lomparvove
REGENXBIO (RGNX) “announced positive long-term follow-up data from the Phase II ALTITUDE(R) study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy using suprac...
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no a...
REGENXBIO Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted late-stage progress in gene therapies for DMD and retinal diseases, with RGX-202 showing strong efficacy, safety, and regulatory momentum toward a 2027 launch. The retina franchise is advancing with pivotal data expected and robust commercial planning, while the Hunter program's clinical hold is under active review.
REGENXBIO Transcript: 2026 Global Healthcare Conference
The conference highlighted late-stage gene therapy programs with strong clinical data in DMD and retina, robust regulatory engagement, and a solid financial runway into 2027. Key programs are advancing toward pivotal data and regulatory filings, with global strategies and commercial readiness underway.
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside ...
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against cer...
Regenxbio price target lowered to $21 from $23 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio (RGNX) to $21 from $23 and keeps a Buy rating on the shares after the FDA had placed…
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
Regenxbio price target lowered to $29 from $32 at Baird
Baird analyst Brian Skorney lowered the firm’s price target on Regenxbio (RGNX) to $29 from $32 and keeps an Outperform rating on the shares. The firm updated its model following…
Regenxbio price target lowered to $32 from $45 at Clear Street
Clear Street analyst Bill Maughan lowered the firm’s price target on Regenxbio (RGNX) to $32 from $45 and keeps a Buy rating on the shares. The firm cites the clinical…